Defining Severe Anemia in Patients With Myelofibrosis

Severe anemia in myelofibrosis is defined as hemoglobin under 8 g/dL or transfusion dependence, requiring management with JAK inhibitors, erythropoietin stimulating agents, or danazol, given its impact on patient prognosis.

EP: 1.Diagnosis and Risk Stratification of Myelofibrosis

EP: 2.Treatment Goals for Patients With Myelofibrosis

EP: 3.Currently Available Treatment Options for Patients With Myelofibrosis

EP: 4.Clinical Experiences With Momelotinib for Patients With Myelofibrosis

Now Viewing

EP: 5.Defining Severe Anemia in Patients With Myelofibrosis

EP: 6.Future of Myelofibrosis Treatment

Recent Videos